Compare Towa Pharmaceutical Co., Ltd. with Similar Stocks
Dashboard
1
The company is Net-Debt Free
- Poor long term growth as Operating profit has grown by an annual rate 7.49% of over the last 5 years
- The company is Net-Debt Free
2
Poor long term growth as Operating profit has grown by an annual rate 7.49% of over the last 5 years
3
The company declared negative results in Mar'26 after flat results in Dec'25
4
With ROCE of 6.51%, it has a attractive valuation with a 1.03 Enterprise value to Capital Employed
5
Underperformed the market in the last 1 year
Stock DNA
Pharmaceuticals & Biotechnology
JPY 216,625 Million (Small Cap)
11.00
NA
0.00%
0.95
8.87%
1.22
Revenue and Profits:
Net Sales:
71,380 Million
(Quarterly Results - Jun 2026)
Net Profit:
5,531 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-0.75%
0%
-0.75%
6 Months
8.67%
0%
8.67%
1 Year
18.62%
0%
18.62%
2 Years
53.28%
0%
53.28%
3 Years
113.05%
0%
113.05%
4 Years
57.43%
0%
57.43%
5 Years
35.6%
0%
35.6%
Towa Pharmaceutical Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
13.83%
EBIT Growth (5y)
7.49%
EBIT to Interest (avg)
27.07
Debt to EBITDA (avg)
4.32
Net Debt to Equity (avg)
1.01
Sales to Capital Employed (avg)
0.66
Tax Ratio
60.11%
Dividend Payout Ratio
75.01%
Pledged Shares
0
Institutional Holding
0.02%
ROCE (avg)
5.76%
ROE (avg)
9.32%
Valuation key factors
Factor
Value
P/E Ratio
11
Industry P/E
Price to Book Value
1.05
EV to EBIT
15.77
EV to EBITDA
8.23
EV to Capital Employed
1.03
EV to Sales
1.41
PEG Ratio
1.12
Dividend Yield
NA
ROCE (Latest)
6.51%
ROE (Latest)
9.73%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
No Signal
Bearish
Bollinger Bands
Bearish
Mildly Bullish
Moving Averages
Bullish (Daily)
KST
Bearish
Bullish
Dow Theory
Mildly Bearish
Mildly Bullish
OBV
Mildly Bearish
No Trend
Shareholding Snapshot : Sep 2012
Shareholding Compare (%holding) 
Majority shareholders
Foreign Institutions
Domestic Funds
Held in 0 Schemes (0%)
Foreign Institutions
Held by 1 Foreign Institutions (0.02%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Jun'26 - QoQ
Jun'26
Mar'26
Change(%)
Net Sales
71,380.00
69,645.00
2.49%
Operating Profit (PBDIT) excl Other Income
11,582.00
9,662.00
19.87%
Interest
628.00
580.00
8.28%
Exceptional Items
1,227.00
-14,000.00
108.76%
Consolidate Net Profit
5,531.00
-11,832.00
146.75%
Operating Profit Margin (Excl OI)
91.30%
51.80%
3.95%
USD in Million.
Net Sales
QoQ Growth in quarter ended Jun 2026 is 2.49% vs -5.36% in Mar 2026
Consolidated Net Profit
QoQ Growth in quarter ended Jun 2026 is 146.75% vs -233.42% in Mar 2026
Annual Results Snapshot (Consolidated) - Mar'26
Mar'26
Mar'25
Change(%)
Net Sales
273,710.00
259,594.00
5.44%
Operating Profit (PBDIT) excl Other Income
45,940.00
43,342.00
5.99%
Interest
2,261.00
1,627.00
38.97%
Exceptional Items
-9,422.00
1,209.00
-879.32%
Consolidate Net Profit
5,250.00
18,986.00
-72.35%
Operating Profit Margin (Excl OI)
84.40%
89.50%
-0.51%
USD in Million.
Net Sales
YoY Growth in year ended Mar 2026 is 5.44% vs 13.89% in Mar 2025
Consolidated Net Profit
YoY Growth in year ended Mar 2026 is -72.35% vs 17.39% in Mar 2025
About Towa Pharmaceutical Co., Ltd. 
Towa Pharmaceutical Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






